penny stocks to buy
Momentum & Growth

4 Penny Stocks to Buy: NWBO ENZC SYSX MULN

Markets are tough right now, but this too shall pass. Just need to ride this out. In the meantime, it’s best to take profits when you can. Also, it’s important to look for penny stocks with long-term potential.

In this article, we take a look at 4 hot penny stocks that can do well in the following weeks. They are Northwest Biotherapeutics, Inc (OTCQB: NWBO), Enzolytics Inc (OTCPK: ENZC), Sysorex, Inc (OTCQB: SYSX), and Mullen Automotive, Inc (NASDAQ: MULN).

Penny Stocks to Buy NWBO

Penny Stocks to Buy ENZC

Penny Stocks to Buy SYSX

Penny Stocks to Buy MULN

Penny Stocks to Buy #1 NWBO

Northwest Biotherapeutics, Inc has been quite volatile this week, as the biotech firm revealed the results of its Phase III trial. Investors were quite disappointed with the results, sending the share price to the lowest level since 2020 on record volumes. The price then rebounded to where it traded in January-April, currently fluctuating near $0.81, down 60% from Monday’s $2.

Our readers should be familiar with this OTCQB member, as we first reported on Northwest Biotherapeutics in September 2020, when it was trading near 70 cents, before surging to the highest level in years at over $2.

The $2 mark was broken again earlier this week, as investors were optimistic that the Phase III results would reveal something valuable.

However, bears jumped on it on Tuesday after the company announced a presentation with Phase III data for its lead asset DCVax-L in Glioblastoma multiforme (GBM) brain cancer, which accounts for almost 50% of brain cancers and is the most aggressive one, with no effective treatments. NWBO’s main candidate is based on its DCVax platform, which is designed to use the activated dendritic cells to trigger a patient’s immune system to attack cancer.

Dr. Paul Mulholland of University College Hospital made the presentation at the Frontiers of Cancer Immunotherapy Conference of the New York Academy of Sciences. The overall results showed that the trial, which involved 331 patients, had met the primary endpoint of overall survival (OS) in newly diagnosed GBM patients after the progression-free survival (PFS) the initial primary endpoint of the trial, was found to be unviable. In fact, according to PFS data, the placebo showed better results:

  • DCVAX-L = 6.2 months PFS.
  • Placebo = 7.6 months PFS.

When it comes to safety, there were five reports of serious adverse events out of 2,193 doses of DCVax-L. The presentation showed that there were no reports of autoimmune reactions or incidences of a cytokine storm.

The only hope for bulls is the possibility that, as the company suggests, the vaccine-induced pseudo-progression (PsPD) may negatively affect the results. PsPD is when a tumor initially expands and then becomes smaller after time.

So, is this probably over? We don’t think so, although we don’t expect a quick recovery. There are several positive aspects to consider. The 15-yearlong study showed that the survival of newly-diagnosed GBM after the therapy was 13% vs 5.7% without the therapy. Also, recurrent GBM was 13.2 months of survival (mOS) with the therapy, vs 7.8 mOS without it. In fact, NWBO’s treatment was the first to show improvement in mOS since Temodar, an aggressive chemo option with worse adverse reactions. Thus, NWBO’s product can be used in combination with other therapies.

Despite the disappointment, NWBO will continue to advance its therapy. The company has already put in a request that the endpoints be updated.

NWBO still can talk to Big Pharma on potential collaboration and/or buyout. The NWBO story isn’t over and there’s a lot more innings to go.

Penny Stocks to Buy #2 ENZC

Enzolytics Inc is another drug development company trading on OTC. Unlike NWBO, ENZC has had a decent week and month, gaining over 5% since Monday. The Pink Current stock is now trading at $0.074, which is 50% lower than the YTD high at the beginning of January.

We got our subscribers in on ENZC last year in October at just $.014 a share, helping many of our subscribers secure profits when the stock almost hit the $1 mark in February 2021. We expect another rally this year, as ENZC sits on a pile of patents and is working on multiple therapies.

ENZC is committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Its flagship compound is ITV-1 – a suspension of Inactivated Pepsin Fragment (IPF), which studies have shown is effective in the treatment of HIV. IPF is the active drug substance of ITV-1 and is a purified extract of porcine pepsin. ITV-1 has been shown to modulate the immune system. IPF is a platform technology that can be used to facilitate a broad range of applications. It is free from major neurological, gastrointestinal, and hematological side effects seen in the anti-retrovirals in use today. IPF has not been shown to be subject to viral resistance and is cost-effective.

In mid-April, the stock bottomed out at the lowest level in over a year, and it tested that support again earlier this month, forming a double bottom pattern. This might be a bullish signal pointing to trend reversal, especially as investors have high expectations of ENZC’s recently launched IPF Immune™, an immune modulator that debuted at ECRM’s “Weight Management, Nutrition, and Vitamin Program.”

Charles S. Cotropia, CEO of Enzolytics, said last month:

“The retail buyers with whom we met represent regional and national food, drug and mass health chains, which are optimum outlets for the company’s product. These retail outlets carry products focused on the $50.11 Billion dietary supplement market, a market in which the company’s product will be widely accepted and appreciated. According to Grand View Research, the 2022 North American dietary supplements market of $50.11 Billion is forecast to increase to $77.10 Billion in 2028.”

ENZC believes IPF Immune™ will meet consumer needs thanks to its significant benefits:

  • It stimulates the immune system to help protect people from infections and diseases, enhances recovery, and reduces the recovery period after an illness.
  • It has a beneficial effect on the immune system, enhancing the body’s ability to fight infections, promoting antibody production, and promoting the body’s antioxidant defenses.
  • IPF Immune™ acts by tagging viruses and bacteria to assist T-cells in addressing them. In this way, it assists the body’s immune helper T-cells in performing their natural function.
  • The protection process that is stimulated is natural and produces no side effects.

Also, it may be used alone or in conjunction with other therapies. The company said that the initial user feedback and user satisfaction had been unprecedented.

IPF Immune can generate significant revenue, as the drug is about to be sold in Walmart, Walgreens, CVS Pharmacy, and other retailers.

This might be a big change for ENZC, and the company even creates a dedicated website for its immune modulator.

Besides this, ENZC recently confirmed that beneficial effects of ITV-1 had been demonstrated in clinical trials in Europe. Meanwhile, the company continues to work on the production of fully human monoclonal antibodies targeting multiple infectious diseases, including SARS-CoV-2 and HIV-1. We think that seven pennies are a very low price for ENZC, especially as it starts generating revenue.

Penny Stocks to Buy #3 SYSX

Sysorex, Inc is an OTCQB crypto play that is recovering from its record low touched at the end of April. We reported on it last week when it was trading at the same level. Exactly one year ago, SYSX was trading at over $9. However, despite strong fundamentals, the bearish pressure has sent the price below $0.005 at the end of April. Since then, the stock has exploded by about 1,000%, which was like a breath of fresh air amid the general bearishness.

SYSX is a data center owner and operator and is the largest US-based, publicly-traded Ethereum mining and blockchain technology company. Following the reverse triangular merger with TTM Digital Assets & Technologies, Inc, SYSX shifted its primary business focus to the mining of Ethereum and opportunities related to the Ethereum blockchain. Even though the company has generated revenue, investors have probably dumped SYSX on expectations that Ethereum mining would become irrelevant given the network’s upgrade to adopt the Proof of Stake (PoS) algorithm, which doesn’t require mining at all. Nonetheless, the full upgrade has been delayed by a few months, and the so-called Merger (when PoS is adopted) will happen in the last quarter of 2022. Moreover, earlier this month, Ethereum miner revenue surged to a single-day all-time high of 95,000 ETH, driven by an expansion in decentralized finance (DeFi) activity.

But this is not the only bullish signal. Last week, SYSX provided a business update, reiterating the deal between its largest shareholders – Bigger Capital Fund, LP and District 2 Capital Fund LP – and Ostendo Technologies, Inc, on which we also reported in our latest post.

Ostendo is a technology company that designed a Quantum Photonic Imager platform, purpose-built, to create next-generation, light field semiconductor chips and augmented reality hardware for consumer, enterprise and defense applications. With the financial backing of industry heavy-weights such as PayPal co-founder Peter Thiel and funding from government agencies including DARPA, Ostendo is the creator of what the funds backing SYSX believe is ground-breaking technology with a wide array of applicability in augmenting reality and enriching the metaverse.

Wayne Wasserberg, CEO of Sysorex, commented:

“While markets have been under severe pressure over the last six or more months given economic news and world events, and this time has seen a commensurate decline in the value of crypto assets, Sysorex firmly believes in the future of the Ethereum Blockchain and the viability of our Sysorex Government Services business. Our anticipated transaction with Ostendo Technologies, Inc., slated to close later this month, is just one example of a number of strategic steps we are undertaking to potentially create substantial value during this market downturn. If our common stock was to remain at these levels following the Ostendo transaction, we would be trading at far less than one-half of book value, which is likely one of the reasons that funds like Bigger Capital and District 2 have identified Sysorex as a deep value opportunity.”

In anticipation of the completion of the Ostendo transaction, SYSX is in active discussions with several New York City-based investment banks to assist with its anticipated uplisting to a national stock exchange. The company will include a listing process update in its next corporate communication expected within a few days.

Despite the recent rally, SYSX is still far away from its $9 mark reached last year. This is a good entry point, especially with Bigger Capital looking to boost shareholder value.

Penny Stocks to Buy #4 MULN

Back in March, we reported on a new EV play that was making waves at the time. Mullen Automotive, Inc, which is trading on NASDAQ, returned back to the $1 mark after a 15% gain on Friday. The stock bottomed out on Thursday below $0.80. MULN seems to form a double bottom pattern, which is a strong bullish signal that anticipates a trend reversal. The first bottom showed up in February near 60 cents, after the stock tumbled from its November ATH at over $15.

We presented our bullish stance on MULN in a dedicated article when the share price was under $1.

MULN is an EV maker that is only starting its journey. It bets on its flagship car, Mullen FIVE EV, which has amazing specs and a gorgeous design. Last year, it won LA Auto Show’s ZEVAS Award for the “Top SUV Zero Emission Vehicle (ZEV)”, with Rivian R1S and Lincoln Aviator Grand Touring also on the list.

MULN CEO David Michery said back then:

“The FIVE is a very competitive EV that was able to go up against an impressive set of competitors, including both legacy brands and exciting new startups. The fact that so many people voted for the FIVE, helping us beat the other finalists, the Rivian R1S and the Lincoln Aviator Grand Touring, by a huge margin to win this award is a tremendous testament to what we are trying to accomplish.”

The FIVE has a promoted range of 325 miles, boasting a bold design with curvy lines. The price starts at $55,000 for the basic model.

On Friday, MULN released the preliminary financials for Q2, which has driven share prices. It reported preliminary cash and equivalents of $65.2 million, primarily due to $43.9 million from the issuance of Series C Preferred Stock and associated warrants. It also received $29.6 million in net proceeds under the $30 million Esousa Equity Line, dated September 1, 2021. Total assets rose about 138.4% to over $100 million, driven by the financing activities. The company’s debt dropped 10.8% q/q to $16.9 million. Stockholders’ equity rose Q/Q from a deficit of -$10.5 million to a surplus of +$52.6 million.

CEO David Michery said:

“Our balance sheet continues to improve and our EV programs are all moving forward, including the start of the Mullen FIVE RS program.”

Earlier this month, Mullen signed a proposal with Thurner Design for the vehicle development of the Mullen FIVE RS, a high-performance EV sport crossover vehicle featuring close to 1,100 HP, 0-60 mph in just 1.95 seconds, and 200 mph top speed. The proposal includes two phases:

  • Design, surfacing, and design support;
  • Visualization and high imaging.

The Thurner Design team is responsible for shaping and directing designs and brands like Rolls-Royce Motorcars, Bentley Motors, Bugatti, Porsche, Lamborghini, and Aston Martin.

We think MULN has great potential if it manages to advance its FIVE models. It has its own facilities in the US and uses proprietary technology to increase the efficiency of its batteries. MULN looks to be a discount entry opportunity at these levels.

THE FINAL NOTE

Now is a great opportunity to invest in top penny stocks with great potential. Our job is to identify the best penny stocks with strong fundamentals and let our subscribers pick the ones they like to build a well-diversified portfolio.

Buying dips and selling rips as swing trades remains the best strategy in the stock market. Still, whenever a hot stock is in the middle of a bull run, we recommend our subscribers to book profits.

It’s very important to eye penny stocks that have room for growth and have yet to make their explosive move. There are plenty of opportunities, and we take our time to monitor hundreds of penny stocks to buy each week, trying to find the best alerts for our subscribers.

Remember, all you need is one or two penny stocks to run in order to crush the market averages.

As always, good luck to all (except the shorts)!

WHEN INSIDER FINANCIAL HAS A STOCK ALERT, IT CAN PAY TO LISTEN. AFTER ALL, OUR FREE NEWSLETTER HAS FOUND MANY TRIPLE-DIGIT WINNERS FOR OUR SUBSCRIBERS. WE SPECIALIZE IN FINDING MOMENTUM BEFORE IT HAPPENS!

Disclosure: We have no position in any of the securities mentioned. We wrote this article ourselves and it expresses our own opinions. We are not receiving compensation for it. We have no business relationship with any company whose stock is mentioned in this article. Insider Financial is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. This article is not a solicitation or recommendation to buy, sell, or hold securities. This article is meant for informational and educational purposes only and does not provide investment advice.

4 Penny Stocks to Buy: NWBO ENZC SYSX MULN
Click to comment
To Top